Boryung Signs Global Supply CDMO Contract with Cheplapharm for 'Zyprexa'

[Financial News] Boryung announced on the 17th that it has signed a contract development and manufacturing (CDMO) contract with global pharmaceutical company Cheplapharm for the global supply of the schizophrenia treatment 'Zyprexa Tablet (ingredient name: Olanzapine)'.
Boryung plans to supply Zyprexa tablets, which will be sold in up to 46 countries including Europe and North America, to Cheplapharm from the end of next year.
Cheplapharm is a global pharmaceutical company based in Germany and Switzerland, supplying medicines to over 145 countries worldwide, and recorded sales of approximately 2.4 trillion won last year.
In 2023, it acquired global rights to Zyprexa, excluding Korea, from global pharmaceutical company Eli Lilly, further strengthening its position in the field of neuropsychiatric disorder treatments.
Boryung is enhancing its pharmaceutical global supply capabilities through cooperation with such global partners. Boryung will export Zyprexa through Cheplapharm's global distribution network from the fourth quarter of next year, depending on the completion of regulatory approvals in the supply countries.
Since acquiring domestic rights to Zyprexa from Lilly in 2021 through the original product acquisition (LBA) method, Boryung has completed the transition to in-house production in 2024 after undergoing global technology transfer and quality equivalence verification.
Through this, Boryung has secured stable production capabilities for Zyprexa centered on the Yesan Campus, and based on this foundation, has begun to globalize the supply of Zyprexa through this contract.
A Boryung official said, "This contract was possible because we secured technical trust based on the Yesan Campus production facilities that meet global standards such as EU-GMP," adding, "In particular, the Yesan Campus is equipped with the latest facilities capable of producing high-quality oral formulations, and being recognized for stability and high-quality production capabilities by global pharmaceutical companies like Cheplapharm is the key background to the contract."
Additionally, Boryung is also pursuing certification from the Brazilian National Health Surveillance Agency (ANVISA). ANVISA is a representative regulatory agency in the Latin American region and is considered a strategic certification for entering the global market.
This contract is the first case of Boryung signing a global CDMO contract in the form of oral formulations, and it is evaluated as a turning point that expands the CDMO capabilities centered on anticancer injectables, which were contracted with Taiwan Lotus last year, to oral formulations, proving the possibility of global expansion based on in-house production.
Kim Seong-jin, Boryung's Chief Sales Officer (CSO), emphasized, "This contract is significant in that Boryung has been recognized for its production capabilities of original blockbuster products and its ability to obtain approvals and supply in 46 countries globally," adding, "We will continue to create opportunities for global expansion of the CDMO business, including expanding various collaborations with Cheplapharm through this cooperation."

vrdw88@fnnews.com Kang Joong-mo Reporter